Ceftolozane/tazobactam is a novel antibiotic approved for the treatment of complicated intra-abdominal and complicated urinary tract infections.
Infections caused by highly resistant bacteria are an increasing challenge for physicians. Ceftolozane/tazobactam is a new antibacterial drug product that combines ceftolozane, a cephalosporin, and tazobactam, a beta-lactamase inhibitor, approved for the treatment of complicated intra-abdominal infections and complicated urinary tract infections. One of its most promising targets is multidrug-resistant Pseudomonas aeruginosa.
Read the publication here.